SCHEMBL3301278

SCHEMBL3301278

CC(C)(C)OC(=O)N(N)CC1CCCNC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPN1 P15169 1/20 0.37
CPB2 Q96IY4 1/20 0.37
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
CYP2D6 P10635 1/20 0.35
EPHX1 P07099 1/20 0.34
GPR88 Q9GZN0 1/20 0.33
BACE1 P56817 2/20 0.33
CHRNB2 P17787 2/20 0.33
CHRNB4 P30926 2/20 0.33
CHRNA3 P32297 2/20 0.33
CHRNA4 P43681 2/20 0.33
SLC6A1 P30531 4/20 0.33
SLC6A11 P48066 3/20 0.33
SLC6A13 Q9NSD5 3/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359460 0.84 USP30 (0.38) CPN1CPB2KMT2AKDM4EMAPT
SCHEMBL3244083 0.84 USP30 (0.38) CPN1CPB2KMT2AKDM4EMAPT
SCHEMBL3253450 0.84 USP30 (0.38) CPN1CPB2KMT2AKDM4EMAPT
SCHEMBL7329124 0.82 ALOX5 (0.43) EPHX1BACE1SLC6A4
SCHEMBL18105288 0.81 POLB (0.34) CPN1CPB2KMT2AEPHX1GPR88
SCHEMBL1782688 0.80 ALOX5 (0.38) KMT2A
SCHEMBL7333606 0.80 CPN1 (0.35) CPN1CPB2KMT2AEPHX1GPR88
SCHEMBL13546948 0.80 CPN1 (0.37) CPN1CPB2KMT2AEPHX1GPR88
SCHEMBL18105275 0.79 CPN1 (0.34) CPN1CPB2KMT2AEPHX1GPR88
SCHEMBL31015390 0.77 SLC6A2 (0.48) CYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE CPN1 1956/4885CPB2 3018/4885KMT2A 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.